Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors.
Ujvari D, Malyukova A, Zovko A, Yektaei-Karin E, Madapura HS, Keszei M, Nagy N, Lotfi K, Björn N, Wallvik J, Stenke L, Salamon D. Ujvari D, et al. Among authors: lotfi k. Oncoimmunology. 2022 Aug 12;11(1):2109861. doi: 10.1080/2162402X.2022.2109861. eCollection 2022. Oncoimmunology. 2022. PMID: 35979386 Free PMC article.
Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?
Richter J, Söderlund S, Lübking A, Dreimane A, Lotfi K, Markevärn B, Själander A, Saussele S, Olsson-Strömberg U, Stenke L. Richter J, et al. Among authors: lotfi k. J Clin Oncol. 2014 Sep 1;32(25):2821-3. doi: 10.1200/JCO.2014.55.6910. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071107 No abstract available.
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, Höglund M, Koskenvesa P, Lotfi K, Majeed W, Markevärn B, Ohm L, Olsson-Strömberg U, Remes K, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J; Nordic CML Study Group. Hjorth-Hansen H, et al. Among authors: lotfi k. Eur J Haematol. 2015 Mar;94(3):243-50. doi: 10.1111/ejh.12423. Epub 2014 Sep 13. Eur J Haematol. 2015. PMID: 25082346 Free PMC article. Clinical Trial.
In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
Skoglund K, Richter J, Olsson-Strömberg U, Bergquist J, Aluthgedara W, Ubhayasekera SJ, Vikingsson S, Svedberg A, Söderlund S, Sandstedt A, Johnsson A, Aagesen J, Alsenhed J, Hägg S, Peterson C, Lotfi K, Gréen H. Skoglund K, et al. Among authors: lotfi k. Ther Drug Monit. 2016 Apr;38(2):230-8. doi: 10.1097/FTD.0000000000000268. Ther Drug Monit. 2016. PMID: 26693810 Free article.
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, Kasanen T, Koskenvesa P, Söderlund S, Höglund M, Markevärn B, Själander A, Lotfi K, Dreimane A, Lübking A, Holm E, Björeman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S. Ilander M, et al. Among authors: lotfi k. Leukemia. 2017 May;31(5):1108-1116. doi: 10.1038/leu.2016.360. Epub 2016 Nov 28. Leukemia. 2017. PMID: 27890936 Free PMC article. Clinical Trial.
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.
Rajala HLM, Missiry ME, Ruusila A, Koskenvesa P, Brümmendorf TH, Gjertsen BT, Janssen J, Lotfi K, Markevärn B, Olsson-Strömberg U, Stenke L, Stentoft J, Richter J, Hjorth-Hansen H, Kreutzman A, Mustjoki S. Rajala HLM, et al. Among authors: lotfi k. J Cancer Res Clin Oncol. 2017 Aug;143(8):1543-1554. doi: 10.1007/s00432-017-2378-6. Epub 2017 Mar 23. J Cancer Res Clin Oncol. 2017. PMID: 28337541
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line.
Kreutzman A, Yadav B, Brummendorf TH, Gjertsen BT, Hee Lee M, Janssen J, Kasanen T, Koskenvesa P, Lotfi K, Markevärn B, Olsson-Strömberg U, Stentoft J, Stenke L, Söderlund S, Udby L, Richter J, Hjorth-Hansen H, Mustjoki S. Kreutzman A, et al. Among authors: lotfi k. Oncoimmunology. 2019 Jul 13;8(9):e1638210. doi: 10.1080/2162402X.2019.1638210. eCollection 2019. Oncoimmunology. 2019. PMID: 31428530 Free PMC article.
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.
Richter J, Lübking A, Söderlund S, Lotfi K, Markevärn B, Själander A, Stenke L, Deneberg S, Ahlstrand E, Myhr-Eriksson K, Panayiotidis P, Gedde-Dahl T, Žáčková D, Mayer J, Olsson-Strömberg U, Mahon FX, Saussele S, Hjorth-Hansen H, Koskenvesa P. Richter J, et al. Among authors: lotfi k. Leukemia. 2021 Aug;35(8):2416-2418. doi: 10.1038/s41375-021-01173-w. Epub 2021 Feb 15. Leukemia. 2021. PMID: 33589755 Free PMC article. No abstract available.
97 results